XOMA to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Webcast on March 11
February 26 2015 - 3:22PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of antibody therapeutics, announced the Company will
host a conference call on Wednesday, March 11, 2015, at 4:30 p.m.
Eastern Standard Time to discuss fourth quarter and full year 2014
financial results and provide an update on gevokizumab's global
clinical programs.
The webcast can be accessed via the Investors & Media
section of XOMA's website at http://investors.xoma.com/events.cfm
and will be available for replay until close of business on June
11, 2015. Telephone numbers for the live audiocast are
877-369-6589 (U.S./Canada) and 408-337-0122
(international).
About XOMA Corporation
XOMA's innovative product candidates are the result of the
Company's expertise in developing ground-breaking monoclonal
antibodies, including allosteric modulating antibodies, which has
created opportunities to develop new classes of therapeutic
antibodies with the potential to treat a wide range of human
diseases. XOMA is developing its lead product gevokizumab (IL-1
beta modulating antibody) with SERVIER through a global Phase 3
program for Behçet's disease uveitis and non-infectious uveitis and
in a Phase 3 program in pyoderma gangrenosum, as well as ongoing
proof-of-concept studies in other IL-1-mediated diseases.
XOMA's scientific research has also produced the XMet
program, which consists of three classes of Selective Insulin
Receptor Modulators (SIRMs) antibodies. XOMA 358, the lead
antibody in the XMet D class, is an allosteric modulating
monoclonal antibody that reduces both the binding of insulin to its
receptor and downstream insulin signaling, and could have a major
effect on the treatment of abnormal metabolic states.
More detailed information can be found at www.xoma.com.
CONTACT: Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024